Hypolag en es it fr

Hypolag Brand names, Hypolag Analogs

Hypolag Brand Names Mixture

  • No information avaliable

Hypolag Chemical_Formula

C56H71N9O23S

Hypolag RX_link

http://www.rxlist.com/cgi/generic4/mycamine.htm

Hypolag fda sheet

Hypolag FDA

Hypolag msds (material safety sheet)

Hypolag MSDS

Hypolag Synthesis Reference

No information avaliable

Hypolag Molecular Weight

1270.28 g/mol

Hypolag Melting Point

No information avaliable

Hypolag H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Hypolag State

Solid

Hypolag LogP

No information avaliable

Hypolag Dosage Forms

Powder for solution (for injection)

Hypolag Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Hypolag Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Hypolag Absorption

No information avaliable

Hypolag side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Hypolag Patient Information

No information avaliable

Hypolag Organisms Affected

Aspergillis, Candida and other fungi